Skip to main content

Practice

ACR Applauds Second Round of Medicare Drug Price Negotiations

ACR

The American College of Rheumatology applauded the announcement of additional drugs subject to pricing negotiations with the Centers for Medicare & Medicaid Services. This second round includes nintedanib (Ofev) and apremilast (Otezla), which are used to treat common and rare rheumatologic

Read Article

Adalimumab Withdrawal in Uveitis Patients

Adalimumab is an effective treatment for JIA-associated uveitis and has been FDA approved for such use - but for how long and can the drug be withdrawn? An adalimumab (ADA) withdrawal trial has shown recurrence of uveitis, arthritis, or both, when the disease was previously controlled on ADA.

Read Article
Do Rheumatologists Follow 2020 ACR Guidelines on Gout? Schlessinger and colleagues report that US Rheumatologists generally adhere to and agree with the 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout, although knowledge gaps and practice… https://t.co/UA7LX016Fl https://t.co/xKKX26vABr
Dr. John Cush @RheumNow( View Tweet )

Weak Data (1.24.2025)

Dr. Jack Cush reviews the news and journal reports from RheumNow.com, and features Dr. Charity Dean, the Keynote speaker at RheumNow Live 2025, and why she is an inspiration.

Read Article

Getting to Remission - Without Biologics

Analysis of data from two early rheumatoid arthritis (ERA) cohorts shows remission in RA is primarily seen in those who do not require biologic DMARDs (bDMARDs), while those needing bDMARDs are less apt to achieve remission.

Read Article

Do Rheumatologists Follow 2020 ACR Guidelines on Gout?

Schlessinger and colleagues report that US Rheumatologists generally adhere to and agree with the 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout, although knowledge gaps and practice variance exists.

A total of 201 US

Read Article

Functional Precision Medicine in Rheumatoid Arthritis

Novels research from the Medical University of Vienna demonstrates the plausible utility of functional precision medicine using immunophenotyping of blood cells with rheumatoid arthritis, to help guide treatment selection.

Read Article

Cardiovascular Risk in Cutaneous Lupus Erythematosus

A retrospective study of cutaneous lupus erythematosus (CLE) patients finds an increased risk of atherosclerotic cardiovascular disease (ASCVD) on par with systemic lupus patients.

An IBM MarketScan Commercial Claims data analysis from 2018 to 2020 included

Read Article
🎉 RheumNow Live 2025 is just about 2 weeks away! 🌟 Don't miss expert talks, interactive panels, networking, and the Karaoke Gong Show! Early registration extended—secure your spot now! 🗓️ Virtual & in-person options available. https://t.co/EPZJMOGgNk https://t.co/cMoOTlWKYu
Dr. John Cush @RheumNow( View Tweet )

Lung Involvement in Still's Disease

A multicentre registry observational study assessed lung involvement in a cohort of Still’s disease patients, affirming pleuritis as most common and that parenchymal lung inflammatory disease is very uncommon in both children and adults.

A total of 90 Still's patients with lung

Read Article

ACR: Congress Fails to Reform PBMs, Mitigate Medicare Cuts

ACR

The American College of Rheumatology (ACR) commended the limited extension of key Medicare telehealth coverage provisions but also expressed disappointment that Members of Congress have failed to pass measures to bring transparency to pharmacy benefit manager (PBM) practices, address flawed

Read Article
QD Clinic - CREST or More? Is this CREST or Diffuse PSS? Features Dr. Jack Cush. QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025 Register at https://t.co/2dcFVgu8z6 https://t.co/h7e2tcOaaF https://t.co/6AceRXb4Nq
Dr. John Cush @RheumNow( View Tweet )
QD Clinic - Treating Overlap with ILD Polyarthritis, ILD, Dermatomyositis - how to treat? Features Dr. Jack Cush. QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025 Register at https://t.co/2dcFVgu8z6 https://t.co/CsIpdS8hyd https://t.co/I92p5U3UTp
Dr. John Cush @RheumNow( View Tweet )

Fallen Angels (1.17.2025)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com; and pays homage to colleagues who passed away in 2024.

Read Article

Childhood Maltreatment and the Risk of Rheumatic Diseases

EurekAlert!

A UK retrospective matched open cohort study shows that children who suffered frmo abuse, neglect or domestic abuse carry a significantly increased risk of developing rheumatoid arthritis or psoriasis in later life.    

Researchers used Dexter software and over 16 million

Read Article

Outcomes of Multisystem Inflammatory Syndrome in Children (MIS-C)

A nationwide cohort study of patients with multisystem inflammatory syndrome in children (MIS-C), a life-threatening complication of COVID-19 infection, showed that many had severe disease during the acute phase, but most recovered quickly and had a reassuring midterm prognosis.

Read Article
🚨 RheumNow Live 2025: Redefining Rheumatology 🚨 Join top experts & innovators shaping the future of rheumatology care! 💡 Cutting-edge research, interactive sessions, expert insights, & exclusive access await. Be part of the change. Register now! 👉 https://t.co/AQbd7NC2wzhttps://t.co/AcmKxGBLvb https://t.co/QlZoAhm8h8
Dr. John Cush @RheumNow( View Tweet )

Screening for Osteoporosis to Prevent Fractures - USPSTF Recommendations

The US Preventive Services Task Force (USPSTF) has done a systematic review on osteoporosis screening to prevent fractures and put forth its recent recommendations. These recommendations pertain to adults 40 years or older with no known diagnosis of osteoporosis or history of fragility

Read Article
QD Clinic - CREST or More? Is this CREST or Diffuse PSS? Features Dr. Jack Cush. QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025 Register at https://t.co/2dcFVgu8z6 https://t.co/eA1GijHiYu https://t.co/3EmN9WAyIR
Dr. John Cush @RheumNow( View Tweet )

BACHELOR Trial - Baricitinib in Early Polymyalgia Rheumatica

Lancet reports a French study demonstrating the efficacy of baricitinib in patients with polymyalgia rheumatica (PMR).

Read Article
Have a rheumatology question or case for Dr. Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/UMrunimVv6 https://t.co/yZNdnAWCy2
Dr. John Cush @RheumNow( View Tweet )

Dazukibart Effective in Adults with Dermatomyositis

Lancet reports that the use of dazukibart, a selective monoclonal antibody against interferon B (IFNβ), was clinically effective in reducing disease activity in adults with active dermatomyositis (DM).

Read Article

Eltrombopag, a Potential New Treatment for ITP

A pilot trial has shown a thrombopoietin receptor agonist, eltrombopag (Promacta), to be effective in connective tissue disease-related (CTD),  refractory immune thrombocytopenia (ITP).

Read Article
EULAR: Considerations when Transitioning from Pediatric to Adult Rheumatologic Care EULAR has established guidance on best practices for delivering patient education in physical activity and self-management of pain during transitional care in rheumatology.… https://t.co/eIqbIENFNV https://t.co/NWjiapEPvP
Dr. John Cush @RheumNow( View Tweet )

Alive in 2025 (1.10.2025)

Dr. Jack Cush brings in the new year with a review of the latest from RheumNow.com

Read Article
×